Bristol-Myers (BMY) Q4 Earnings & Sales Beat, Stock Gains
Bristol-Myers' (BMY) fourth-quarter 2023 earnings and sales surpass estimates as Reblozyl and Revlimid outperform. Shares rise on the same.
Bristol Myers Squibb Tops Earnings Estimates, Boosted by New Drug Sales
Bristol Myers Squibb (BMY) shares edged 0.7% higher in intraday trading Friday after posting better-than-expected results and guidance as it benefited from the addition of new drugs to its lineup.
Bristol Myers' New Drugs Drive Upbeat Outlook. The Stock Is On the Mend.
Bristol Myers Squibb's fourth-quarter earnings and revenue beat Wall Street expectations.
Bristol Myers posts better-than-expected 4th-quarter results
Drugmaker Bristol Myers Squibb on Friday posted better-than-expected results for the fourth quarter as sales of its new anemia drug Reblozyl and its already off patent blood cancer drug Revlimid ou...
Bristol Myers Squibb results top expectations as newer drugs help fuel growth
Bristol Myers Squibb Co. BMY, -0.41% on Friday reported fourth-quarter results that beat analysts' expectations, helped by portfolio stalwarts like the blood thinner Eliquis as well as strong growt...
Bristol Myers' (BMY) sBLAs for Breyanzi Get FDA Priority Tag
Bristol Myers' (BMY) two sBLAs for Breyanzi in relapsed/refractory follicular lymphoma and relapsed/refractory mantle cell lymphoma receive FDA acceptance and priority review.
Healthy Returns: J&J, Merck and Bristol Myers Squibb are in the hot seat
J&J, Merck and Bristol Myers Squibb face a pivotal few weeks ahead. Meanwhile, Apple will reportedly explore health applications for the Vision Pro headset.
Wall Street's Insights Into Key Metrics Ahead of Bristol Myers (BMY) Q4 Earnings
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Bristol Myers (BMY), delve into some of its key metrics to gain a deeper insight into the company's potential performance fo...
Bristol Myers Squibb (BMY) Increases Yet Falls Behind Market: What Investors Need to Know
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $49.87, denoting a +0.34% change from the preceding trading day.
3 Healthcare Stocks at 52-Week Lows: Buy or Bye?
Healthcare stocks trudged through what was a terrible 2023 for the sector. While the S&P 500 rose by 24% during 2023, the healthcare sector managed paltry returns of 0.3%.
What You Need to Know Ahead of Bristol-Myers (BMY) Q4 Earnings
Investors are likely to focus on Opdivos demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.
Dividend Harvesting Portfolio Week 151: $15,100 Allocated, $1,331.13 In Projected Dividends
Dividend Harvesting Portfolio Week 151: $15,100 Allocated, $1,331.13 In Projected Dividends
7 Beaten-Down Value Stocks Poised for an Epic Turnaround
With the S&P 500 reaching new highs last week, investors appear to be taking an optimistic view of the overall stock market. However, not all stocks are participating in this rally.
Bristol-Meyers Stock Seeing Layers of Pressure
After eight-straight monthly losses starting in April 2023, the shares of pharmaceutical concern Bristol-Meyers Squibb Co (NYSE:BMY) started to rebound in December, though were swiftly rejected by ...
FDA Demands "Boxed Warning" to CAR T-Cell Therapy Labels
The FDA directs companies like NVS, BMY, GILD and others to add "boxed warning" to the labels of their CAR T-cell immunotherapies after it identified adverse events.
Related Companies